Evidence map›Paper›PMID 20003447›Full record

ArticleBMC cancer2009

Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.

Ryan J Hartmaier, Sandrine Tchatchou, Alexandra S Richter, Jay Wang, Sean E McGuire, Todd C Skaar, Jimmy M Rae, Kari Hemminki, Christian Sutter, Nina Ditsch and 11 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The function of steroid receptor coactivator-1 in normal tissues and cancer.International journal of biological sciences · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 3 countries.

Ryan J HartmaierProgram in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA. hartmaie@bcm.edu
Sandrine Tchatchou
Alexandra S Richter
Jay Wang
Sean E McGuire
Todd C Skaar
Jimmy M Rae
Kari Hemminki
Christian Sutter
Nina Ditsch
Peter Bugert
Bernhard H F Weber
Dieter Niederacher
Norbert Arnold
Raymonda Varon-Mateeva
Barbara Wappenschmidt
Rita K Schmutzler
Alfons Meindl
Claus R Bartram
Barbara Burwinkel
Steffi Oesterreich
Baylor College of Medicine · USHeidelberg University · DEUniversity Hospital Cologne · DECharité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DEHeinrich Heine University Düsseldorf · DEIndiana University – Purdue University Indianapolis · USKarolinska Institutet · SEKlinikum rechts der Isar · DELudwig-Maximilians-Universität München · DEUniversity of Lübeck · DEUniversity of Michigan–Ann Arbor · USUniversity of Regensburg · DE

Funding

TUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9M
TAMAXIFEN PHARMACOGENETICSU01GM061373 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FLOCKHART, DAVID ALASTAIR · 2000 to 2009
$17.0M
Howard Hughes Medical InstituteNCI NIH HHS CA58183NIGMS NIH HHS U-01 GM61373
6 · The paper itself

Abstract

backgroundCoregulator proteins are "master regulators", directing transcriptional and posttranscriptional regulation of many target genes, and are critical in many normal physiological processes, but also in hormone driven diseases, such as breast cancer. Little is known on how genetic changes in these genes impact disease development and progression. Thus, we set out to identify novel single nucleotide polymorphisms (SNPs) within SRC-1 (NCoA1), SRC-3 (NCoA3, AIB1), NCoR (NCoR1), and SMRT (NCoR2), and test the most promising SNPs for associations with breast cancer risk.

methodsThe identification of novel SNPs was accomplished by sequencing the coding regions of these genes in 96 apparently normal individuals (48 Caucasian Americans, 48 African Americans). To assess their association with breast cancer risk, five SNPs were genotyped in 1218 familial BRCA1/2-mutation negative breast cancer cases and 1509 controls (rs1804645, rs6094752, rs2230782, rs2076546, rs2229840).

resultsThrough our resequencing effort, we identified 74 novel SNPs (30 in NCoR, 32 in SMRT, 10 in SRC-3, and 2 in SRC-1). Of these, 8 were found with minor allele frequency (MAF) >5% illustrating the large amount of genetic diversity yet to be discovered. The previously shown protective effect of rs2230782 in SRC-3 was strengthened (OR = 0.45 [0.21-0.98], p = 0.04). No significant associations were found with the other SNPs genotyped.

conclusionsThis data illustrates the importance of coregulators, especially SRC-3, in breast cancer development and suggests that more focused studies, including functional analyses, should be conducted.

Indexed as

Polymorphism, Single NucleotideAdolescentAdultAgedAged, 80 and overBlack or African AmericanBreast NeoplasmsFemaleGenotypeHumansMaleMiddle AgedNuclear Receptor CoactivatorsRisk FactorsWhite PeopleYoung AdultNuclear Receptor Coactivators

Identifiers

PMID20003447
PMCPMC2804710
OpenAlexW2062971027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.